China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its best-in-class antibody drug conjugate (ADC) CPO301 has received another fast-track status in the United States for the treatment of non-small cell lung cancer (NSCLC). The EGFR targeted ADC has been granted this status for the treatment of epidermal growth factor receptor (EGFR) over-expressed patients with recurrent or metastatic squamous NSCLC who have experienced disease progression on or after platinum-based chemotherapy and anti-PD-(L)1 treatment.
Previously in June 2023, CPO301 was awarded fast-track status in the US for the treatment of recurrent/refractory (R/R) or EGFR targeted therapy ineffective metastatic EGFR mutant NSCLC. Phase I clinical trials conducted in China and the US demonstrated encouraging efficacy and satisfactory safety and tolerability of CPO301 in patients with recurrent or metastatic squamous NSCLC. – Flcube.com
